People

Eva Canaan’s practice focuses on the strategic development and coordination of the scientific defense in pharmaceutical and medical device products liability litigation. In addition to her law degree, Eva holds a Masters in Epidemiology from Columbia University.  Eva is adept at challenging expert witness testimony in depositions and Daubert briefs in federal and state courts.

Eva focuses on making complex scientific concepts accessible to judges and juries.  She routinely works with experts in a variety of scientific disciplines, including epidemiology, toxicology, teratology, and clinical medicine.  Going beyond bottom-line conclusions, Eva aggressively interrogates the data and methodology of studies and reports, often exposing flaws and weaknesses glossed over by the authors and plaintiffs’ experts.  She has deposed plaintiffs’ main causation experts and drafted Daubert and Frye briefs in high-stakes litigations affecting hundreds of cases.  Eva follows the epidemiological literature related to her clients’ products – both in and outside of the litigation context -- and provides real-time analyses and risk-assessments to her clients.  

Full Bio

Credentials

M.S., Columbia University

J.D., Benjamin N. Cardozo School of Law

B.A., New York University, summa cum laude

New York

U.S. District Court for the Eastern District of New York

U.S. District Court for the Southern District of New York

New York State Bar Association - Torts, Insurance and Compensation Law Section

Georgian

Russian

Named New York Metro Super Lawyers®


Rising Star, 2014

Icon close

Close

Recognition

Named New York Metro Super Lawyers®


Rising Star, 2014

Matters

Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).

Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).

Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.

See more
Icon close

Close

Matters

Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).

Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).

Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.

Represented major pharmaceutical company in multidistrict litigation relating to allegations of heart attack and stroke from an anti-diabetic medication.

Insights

Article · Source: Law360

June 17, 2020
MDL Decisions Demonstrate The Need For Rule 702 Reform

View all

Matters

Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).

Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).

Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.

See more
Icon close

Close

Matters

Representing a major pharmaceutical company in federal multidistrict litigation relating to allegations of birth defects from an anti-emetic medication. Deposed plaintiffs’ main causation experts to obtain key admissions to support pending Daubert challenges to exclude the experts’ opinions. Successfully briefed motions related to an epidemiological study relied upon by plaintiffs’ experts, revealing undisclosed conflicts of interest, including funding of the study by plaintiffs’ counsel. In re: Zofran (Ondansetron) Prods. Liab. Litig., 392 F.Supp.3d 179 (D. Mass. 2019), In re: Zofran (Ondansetron) Prods. Liab. Litig., No. 1:15-md-2657, 2020 WL 1550563 (D. Mass. Apr. 1, 2020).

Represented major pharmaceutical company in federal and state litigation relating to allegations of birth defects from an anti-depressant medication. Successfully briefed Daubert motion excluding plaintiffs’ general and specific causation experts. Frischhertz v. SmithKline Beecham Corp., No. CIV.A.10-2125, 2012 WL 6697124 (E.D. La. Dec. 21, 2012).

Represented major pharmaceutical company in state and federal litigation relating to allegations of neurological injuries from a denture adhesive product.

Represented major pharmaceutical company in multidistrict litigation relating to allegations of heart attack and stroke from an anti-diabetic medication.

Insights

Article · Source: Law360

June 17, 2020
MDL Decisions Demonstrate The Need For Rule 702 Reform

View all

Credentials

M.S., Columbia University

J.D., Benjamin N. Cardozo School of Law

B.A., New York University, summa cum laude

New York

U.S. District Court for the Eastern District of New York

U.S. District Court for the Southern District of New York

New York State Bar Association - Torts, Insurance and Compensation Law Section

Georgian

Russian

Named New York Metro Super Lawyers®


Rising Star, 2014

Icon close

Close

Recognition

Named New York Metro Super Lawyers®


Rising Star, 2014